eli lilly & co s tirzepatide Lilly's weight-loss drug reduces sleep apnea severity in late-stage trials Lilly releases Zepbound® (tirzepatide) single-dose

Tirzepatide is a prescription medication that acts as a GIP and GLP-1 receptor agonist

Since tirzepatide is a subcutaneous injection, stomach contents do not affect absorption

The reconstitution chart covers all options with step-by-step instructions

Weight loss comparison at equivalent time points: Real-world data from the SURPASS trials (for diabetes) showed tirzepatide at 15 mg produced 2.4 kg greater weight loss than semaglutide 1 mg at 40 weeks

This is why the 60 mg format is most popular among those who have already titrated to maintenance doses

This can lead to aspiration pneumonitis, pneumonia, or respiratory complications during anesthesia induction